Medical/Pharmaceuticals
Ildong Pharmaceutical starts Phase 1 study of new diabetes therapy in Germany
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- A Phase 1 study on new drug candidate IDG16177 of novel oral treatment for type 2 diabetes, which is being developed by Ildong Pharmaceutical, is initiated inGermany. On June 28th (local time), Ildong Pharmaceutical obtained approval for the Phas...
2021-07-01 21:00
2439
First Naturally-designed and Personalised Bioprosthesis SingValve Set to Revolutionise Heart Valve Surgery
SINGAPORE, July 1, 2021 /PRNewswire/ -- A naturally-designed human-like personalised heart valve bioprosthesis developed by a team of clinician-scientists from theNational University Health System (NUHS) looks set to be a game changer in the next generation of "personalised medicine" and further...
2021-07-01 21:00
3076
Korea National Institute of Health (KNIH) conducts field inspection of companies with mRNA technology
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- Korea National Institute of
Health (KNIH), Korea's top research center in the field of hygiene and medicine
(with Mr. Kwon Jun-Wook as President) conducted a field inspection of key
companies with mRNA technology.
2021-07-01 21:00
2319
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
* First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors * China sites to join the dose expansion part of the study to accelerate TJ- CD4B/ABL111 development * Results of TJ-L14B/ABL503 preclinical studies accepted for publica...
2021-07-01 20:00
13528
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's
MELBOURNE, Australia and SAN FRANCISCO, July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The patent secures a ...
2021-07-01 19:50
13814
Bactiguard receives payment from Zimmer Biomet
STOCKHOLM, July 1, 2021 /PRNewswire/ -- Following successful European regulatory clearance and market launch of Bactiguard-coated Zimmer Biomet trauma implants (ZNN Bactiguard), the initialUSD 1 million milestone payment has been released. "I am excited about our partnership with Zimmer Biomet a...
2021-07-01 17:47
1663
InDevR Launches VaxArray Polio Kit for Faster, Multiplexed Vaccine Characterization
BOULDER, Colo., July 1, 2021 /PRNewswire/ -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray® Polio D-antigen quantification kit for r...
2021-07-01 15:00
1713
Elliott Publishes Letter on GlaxoSmithKline
Elliott believes GSK has a substantial value creation opportunity – 45% upside in its share price – ahead of Consumer Health separation and greater beyond Despite its strengths, GSK has a poor record of operational execution and value creation, leading to scepticism about the Company's future, an...
2021-07-01 14:45
2028
Joint Commission International publishes fourth edition of International Accreditation Standards for Laboratories
Standards and policies in latest edition become effective 1 January 2022 OAK BROOK, Ill., July 1, 2021 /PRNewswire/ -- Joint Commission International (JCI) today publishedJoint Commission International Accreditation Standards for Laboratories, Fourth Edition. The manual provides requirements for ...
2021-07-01 08:00
1554
European Wellness partners with China's provincial government to advance Education in Biological Regenerative Medicine
EDENKOBEN, Germany, July 1, 2021 /PRNewswire/ – European Wellness Biomedical Group (European Wellness) through its educational arm, European Wellness Academy (EWA), has signed a Letter of Intent (LOI) withZhifu People's Government of Yantai City,Shandong Province, China to establish the first In...
2021-07-01 08:00
4454
Joint Commission International publishes fourth edition of International Accreditation Standards for Laboratories
Standards and policies in latest edition become effective 1 January 2022 OAK BROOK, Ill., July 1, 2021 /PRNewswire/ -- Joint Commission International (JCI) today publishedJoint Commission International Accreditation Standards for Laboratories, Fourth Edition. The manual provides requirements for ...
2021-07-01 08:00
1959
Zimmer Biomet announces partnership with OSSIS as exclusive Asia Pacific distributor for patient-specific 3D printed titanium hip replacement joints
SINGAPORE, July 1, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced a partnership with OSSIS to serve as the exclusiveAsia Pacific distributor for its patient-specific 3D printed titanium hip replacement joints. ...
2021-07-01 08:00
5548
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
SYDNEY, June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points * GBM AGILE pivotal study of paxalisib is...
2021-06-30 22:00
30672
VUNO Inks Deal with Samsung Electronics to Embed AI-powered Algorithms in Samsung's Premium Mobile X-ray System
SEOUL, South Korea, June 30, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc., announced today a partnership with Samsung Electronics Co., Ltd., global medical device company to incorporate its AI-powered chest X-ray diagnostic solution, VUNO Med®-Chest X-ray™, ...
2021-06-30 21:00
1872
I-Mab Honored with Top Rankings by Institutional Investor
SHANGHAI and GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it was ranked among the top companies by leading gl...
2021-06-30 20:00
12944
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines
Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its pipeline and scale production in global markets MENLO PARK, Calif., June 30, 2021 /PRNewswire/ -- Antheia, a synthetic biology company enabling next-generation ...
2021-06-30 20:00
2378
Mentice receives order of total SEK 5.9 million from Baylis Medical Company
STOCKHOLM, June 30, 2021 /PRNewswire/ -- Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on interventional procedures, has entered into an agreement withBaylis Medical Company ("Baylis")to provide simulation solutions. Based on t...
2021-06-30 18:19
1580
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
HONG KONG, June 30, 2021 /PRNewswire/ -- Akeso, Inc. ("Akeso" or the "Company", stock code: 9926.HK) is pleased to announce today that, Akesohas been awarded as "Most Honored Company" in the "2021 All-Asia Executive Team" survey published byInstitutional Investor, and has been ranked top 3 in all...
2021-06-30 16:00
13686
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
* Clover to procure CpG 1018 adjuvant from Dynavax for use in the commercial production of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) * Pending conditional regulatory approvals, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) by the end of 2021 CHENGDU,...
2021-06-30 16:00
5656
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover's COVID-19 Vaccine for the COVAX Facility
* Pending WHO EUL for its COVID-19 vaccine candidate, Clover is committed to providing 64 million doses in 2021 and Gavi has options for an additional 350 million doses in 2022 * Clover will receive a significant upfront payment, a payment upon positive Phase 2/3 data, potential payments upon...
2021-06-30 16:00
2811
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
5428
